Navigation Links
AbbVie Reports Third-Quarter 2013 Financial Results
Date:10/25/2013

ternal affairs and general counsel;  Scott Brun, vice president of clinical development;  and Larry Peepo, vice president of investor relations.  The call will be webcast through AbbVie's Investor Relations Web site at www.abbvieinvestor.com.  An archived edition of the call will be available after 11:00 a.m. Central time.

Non-GAAP Financial Results Financial results for 2013 are presented on both a reported and a non-GAAP basis.  Reported results were prepared in accordance with GAAP and include all revenue and expenses recognized during the period.  Non-GAAP results adjust for certain non-cash items and for factors that are unusual or unpredictable, and exclude those costs, expenses, and other specified items presented in the reconciliation tables later in this release.  AbbVie's management believes non-GAAP financial measures provide useful information to investors regarding AbbVie's results of operations and assist management, analysts, and investors in evaluating the performance of the business.  Non-GAAP financial measures should be considered in addition to, and not as a substitute for, measures of financial performance prepared in accordance with GAAP.  The company's 2013 financial guidance is also being provided on both a reported and a non-GAAP basis. 

Forward-Looking StatementsSome statements in this news release may be forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995.  The words "believe," "expect," "anticipate," "project" and similar expressions, among others, generally identify forward-looking statements.  AbbVie cautions that these forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially from those indicated in the forward-looking statements.  Such risks and uncertainties include, but are not limited to, challenges to intell
'/>"/>

SOURCE AbbVie
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10

Related medicine technology :

1. AbbVie Named a Science Top Employer
2. AbbVie To Present Investigational Data From Phase II Hepatitis C Program At The Liver Meeting
3. AbbVie and Galapagos to Co-Develop Cystic Fibrosis Therapies
4. Strong Sales and Healthcare Reforms Benefit Earnings - Research Report on Gilead, Pfizer, Merck, AbbVie, and LifePoint
5. After Reviewing Brief Product Profiles, Surveyed Physicians Believe that Likely Candidates for Late-Phase Chronic Kidney Disease Products from AbbVie, Mitsubishi Tanabe, Eli Lilly, Concert, Fibrogen and Pfizer are Typically Stage 3b and 4 Patients
6. AbbVie Declares Quarterly Dividend
7. AbbVie Presents Preliminary Results from Phase I Study of Investigational Oncology Compound ABT-199/GDC-0199 in Patients with High-Risk Chronic Lymphocytic Leukemia (CLL) at European Hematology Association Annual Meeting
8. For Treating Psoriatic Arthritis, Clinical Data and Thought Leaders Opinions Indicate that AbbVie/Eisais Humira Has the Best Clinical Profile Among Key Marketed Therapies
9. AbbVie to Participate in 2013 Jeffries Global Healthcare Conference
10. AbbVie Initiates Phase 3 Study of Its Investigational Compound Atrasentan on Renal Outcomes in Patients with Diabetic Nephropathy
11. AbbVie and Galapagos Extend GLPG0634 Collaboration to Include Crohns Disease
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/22/2014)... and AUSTIN, Texas ... and PureMHC LLC today announced they have entered ... novel antibody-based immunotherapies designed to target cancers. ... phosphorylated peptides displayed on the surfaces of tumor ... tumor targets (PTTs), derived from proteins that play ...
(Date:10/22/2014)... , Oct. 22, 2014  AcelRx Pharmaceuticals, ... that results from the  IAP310 study have been ... (RAPM), a peer-reviewed journal with broad, multidisciplinary ... trial evaluating the safety and efficacy of Zalviso, ... system (SSTS), for the treatment of post-operative pain ...
(Date:10/22/2014)... Calif. , Oct. 22, 2014 /PRNewswire/ ... ), a biopharmaceutical company leading the discovery ... today announced that it has demonstrated human ... ongoing clinical study evaluating RG-101, a wholly-owned, ... treatment of hepatitis C virus infection ("HCV").  ...
Breaking Medicine Technology:Biotech Companies To Co-Discover And Co-Develop Antibodies Targeting Novel Phosphopeptide Tumor Targets 2AcelRx Announces Publication of Zalviso Phase 3 Abdominal Trial Results 2A Single Subcutaneous Dose of 2mg/kg of RG-101, Regulus' Wholly-Owned, GalNac-Conjugated anti-miR Targeting microRNA-122, Demonstrates 4.1 log10 Mean Viral Load Reduction as Monotherapy at Day 29 in Patients with Varied HCV Genotypes and Treatment H 2A Single Subcutaneous Dose of 2mg/kg of RG-101, Regulus' Wholly-Owned, GalNac-Conjugated anti-miR Targeting microRNA-122, Demonstrates 4.1 log10 Mean Viral Load Reduction as Monotherapy at Day 29 in Patients with Varied HCV Genotypes and Treatment H 3A Single Subcutaneous Dose of 2mg/kg of RG-101, Regulus' Wholly-Owned, GalNac-Conjugated anti-miR Targeting microRNA-122, Demonstrates 4.1 log10 Mean Viral Load Reduction as Monotherapy at Day 29 in Patients with Varied HCV Genotypes and Treatment H 4A Single Subcutaneous Dose of 2mg/kg of RG-101, Regulus' Wholly-Owned, GalNac-Conjugated anti-miR Targeting microRNA-122, Demonstrates 4.1 log10 Mean Viral Load Reduction as Monotherapy at Day 29 in Patients with Varied HCV Genotypes and Treatment H 5A Single Subcutaneous Dose of 2mg/kg of RG-101, Regulus' Wholly-Owned, GalNac-Conjugated anti-miR Targeting microRNA-122, Demonstrates 4.1 log10 Mean Viral Load Reduction as Monotherapy at Day 29 in Patients with Varied HCV Genotypes and Treatment H 6A Single Subcutaneous Dose of 2mg/kg of RG-101, Regulus' Wholly-Owned, GalNac-Conjugated anti-miR Targeting microRNA-122, Demonstrates 4.1 log10 Mean Viral Load Reduction as Monotherapy at Day 29 in Patients with Varied HCV Genotypes and Treatment H 7A Single Subcutaneous Dose of 2mg/kg of RG-101, Regulus' Wholly-Owned, GalNac-Conjugated anti-miR Targeting microRNA-122, Demonstrates 4.1 log10 Mean Viral Load Reduction as Monotherapy at Day 29 in Patients with Varied HCV Genotypes and Treatment H 8
... YORK, Sept. 23 Reportlinker.com announces that a ... catalogue: Genzyme Corporation: PharmaVitae Profile ... Introduction This analysis examines the historical ... pharmaceutical sector. The profile encompasses global company strategy, ...
... Calif., Sept. 23 Preclinical data of a ... blood pressure) was presented Tuesday, September 21st, at ... Washington, DC, by Christopher D. Owens, MD, MSc, ... Endovascular Surgery, University of California, San Francisco. The ...
Cached Medicine Technology:Reportlinker Adds Genzyme Corporation: PharmaVitae Profile 2Reportlinker Adds Genzyme Corporation: PharmaVitae Profile 3Reportlinker Adds Genzyme Corporation: PharmaVitae Profile 4Reportlinker Adds Genzyme Corporation: PharmaVitae Profile 5Reportlinker Adds Genzyme Corporation: PharmaVitae Profile 6Reportlinker Adds Genzyme Corporation: PharmaVitae Profile 7Promising New Therapy for Drug-Resistant Hypertension Presented at Interventional Cardiology Meeting in Washington, D.C. 2
(Date:10/22/2014)... Shriners Hospitals for Children® and UK HealthCare have ... of Shriners Hospitals for Children - Lexington from 1900 ... of Kentucky Albert B. Chandler Hospital. The new facility ... operated by Shriners Hospitals for Children, and designed to ... families well into the future. , “The quality care ...
(Date:10/22/2014)... 22, 2014 Best Cheap Hosting USA ... world. The site has recently announced that iPower ( ... for people from around the world. , “iPower is ... today and is providing various kinds of useful products ... insists on offering excellent customer service and a number ...
(Date:10/22/2014)... King of Prussia, PA (PRWEB) October 22, 2014 ... Group, is recognized as an industry leader with over ... industry award winning team leader in the areas related ... In addition, Mr. Carlson is an Editorial Advisory Board ... Group Healthcare Council Educator. Blue Fin Group is ...
(Date:10/22/2014)... HealthDay Reporter , TUESDAY, Oct. 21, 2014 ... lead to increased blood pressure, according to a new study. ... blood pressure for young adult women or for teenagers, according ... lightly or moderately, their risk of high blood pressure was ... studies in older adult men and women," said lead researcher ...
(Date:10/20/2014)... Texas (PRWEB) October 20, 2014 The ... the must-have source of thousands of facts, figures and ... countries and 68 medical sector forecast categories the ... with global, regional and national views on the worldwide ... outlook. , The report gives you data for 2010-2019, ...
Breaking Medicine News(10 mins):Health News:Shriners Hospitals for Children - Lexington Announces Plan to Build New $47 Million Facility 2Health News:Shriners Hospitals for Children - Lexington Announces Plan to Build New $47 Million Facility 3Health News:Best Cheap Hosting USA Has Recently Announced The Best Cheap Web Hosting Companies In 2014 2Health News:Rich Carlson and Marc Duey to Hold Workshop at CBI’s Specialty Pharmacy and Distribution Networks Conference 2Health News:Binge Drinking May Boost Blood Pressure in Young Men 2Health News:Binge Drinking May Boost Blood Pressure in Young Men 3Health News:Binge Drinking May Boost Blood Pressure in Young Men 4Health News:Worldwide Medical Market Forecasts to 2019 a New Research Report Added to ReportsnReports.com 2Health News:Worldwide Medical Market Forecasts to 2019 a New Research Report Added to ReportsnReports.com 3Health News:Worldwide Medical Market Forecasts to 2019 a New Research Report Added to ReportsnReports.com 4
... physicians for outpatient surgeries for bladder cancer have led ... procedures being performed and an overall increase in cost ... a new study published early online in Cancer ... The findings indicate that some Medicare policies aimed at ...
... the risk of developing asthma after the menopause, suggests a ... Thorax . The authors base their findings on ... HRT and development of asthma symptoms every two years between ... in the French E3N study, which includes almost 100, 000 ...
... ... ‘state-of-the-art’ building , ... Vancouver, Washington (PRWEB) February 7, 2010 -- Safetec Compliance Systems, Inc. ... Washington, effective immediately. The new office is located at 7700 NE Parkway Drive, ...
... ... culture, customs, history and music will open Feb. 28th in the St. Louis Jewish Community ... St. Louis, MO ... for Purim, an annual Jewish observance. The new museum is located inside the St. Louis ...
... , , Physician Assistant Foundation, Baylor College ... , HOUSTON , Feb. 6 The ... other local partners today unveiled their unique approach to providing health ... with hopes the program could become a model for meeting similar ...
... ... lift at his practice offering plastic surgery in Phoenix . For women who are ... popularity of cosmetic enhancement with breast implants. , ... Phoenix, AZ (Vocus) February 6, 2010 -- Over the course of his ...
Cached Medicine News:Health News:Medicare reimbursement change meant to save money has opposite effect 2Health News:Estrogen-only HRT may increase risk of asthma after menopause 2Health News:Safetec Compliance Systems Announces Expansion 2Health News:Community Health Navigator Program to Fill Gaps in Care for Houston's Burmese Refugees 2Health News:Community Health Navigator Program to Fill Gaps in Care for Houston's Burmese Refugees 3Health News:Community Health Navigator Program to Fill Gaps in Care for Houston's Burmese Refugees 4Health News:Is Breast Augmentation Surgery Right for Me? Arizona Breast Surgeon Discusses Various Breast Procedures 2Health News:Is Breast Augmentation Surgery Right for Me? Arizona Breast Surgeon Discusses Various Breast Procedures 3
... microscopic documentation. The Leica DC480 digital camera ... fidelity, resolution and detail. Even with low ... to perfect images due to the integrated ... modes make this camera the best choice ...
Coolpix 5000 microscope package includes Coolpix 5000 digital camera, MDC-A relay lens, EH52 AC adapter, UR-E6 step-down adapter ring, EU-1 wired remote control unit....
... Geometric Data Hemastainer. Formulated to ... quality control tested on human ... staining and absence of precipitate. ... a minimum of eight hours ...
Wright Stain Solutions...
Medicine Products: